您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SX-682
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SX-682
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SX-682图片
CAS NO:1648843-04-2
规格:≥98%
包装与价格:
包装价格(元)
1mg电议
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 467.20
FormulaC19H14BF4N3O4S
CAS No.1648843-04-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 10mM
Water: <1 mg/mL
Ethanol: <1 mg/mL
Chemical Name(2-(((5-((4-fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid
SynonymsSX-682; SX 682; SX682
SMILES CodeO=C(C1=CN=C(SCC2=CC(OC(F)(F)F)=CC=C2B(O)O)N=C1)NC3=CC=C(F)C=C3
实验参考方法
In Vitro

In vitro activity: SX-682 is a novel, potent and selective CXCR2 chemokine receptor antagonist with potential anticancer activities. The CXC chemokine receptor CXCR2 is upregulated in a variety of different tumor cell types and involved in tumor cell proliferation and progression. Inhibition of CXCR2 led to reduced metastasis and decreased tumorigenesis. As a CXCR2 antagonist, SX-682 has the potential to treat cancer such as castration-resistant prostate cancer and melanoma. SX-682 in combination with pembrolizumab for the treatment of metastatic melanoma is starting phase I clinical trial by Syntrix Biosystems, Inc.


Kinase Assay:


Cell Assay:

In VivoSX-682 was orally administered twice a day at 50 mg/kg actual dose on a Monday through Friday schedule. Similar drug dosing methods were described previously
Animal model
Formulation & Dosage 50 mg/kg; p.o.
References Nature. 2017 Mar 30;543(7647):728-732.